HK-listed Metis TechBio climbs on deal with Eli Lilly
Tue 02:49
BUZZ-HK-listed Metis TechBio climbs on deal with Eli Lilly ** Shares of Metis TechBio 7666.HK climb 6.5% to HK$12.69, their highest level since October 13
** The Chinese artificial intelligence-driven nanomaterial platform technologies developer said on Monday it entered into a collaboration agreement with Eli Lilly LLY.N
** Agreement worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies
** Metis will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues
** Since debut on May 13, Metis stock up 13.3% from the offer price of HK$10.50 apiece
** YTD, Hang Seng Biotech Index .HSBIO up 4.3%
(Reporting by Donny Kwok)
Recent news on Metis TechBio
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
HK-listed Metis TechBio climbs on deal with Eli Lilly
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion (updated)
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech